Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Researchers sought to develop an NLP model to describe patients and tumor characteristics to more easily aggregate data.
Is there a better way to manage low-grade NMIBC? Adding UGN-102 to the current standard of care may be the answer.
Results of the phase 2b SunRISe-1 trial showed TAR-200 yields complete responses in BCG-unresponsive high-risk NMIBC.
The TAR-210 delivery system provides a continuous release of erdafitinib to the bladder while limiting systemic toxicities.
An LBA shed light on the effects of erdafitinib in patients with high-risk NMIBC with select FGFR alterations after BCG.
This review highlights some of the most exciting abstracts and presentations in GU oncology at the ESMO Congress 2023.
Dr. Black shares the basis for testing atezolizumab in BCG-unresponsive NMIBC as well as the implications of SWOG S1605.
Dr. Satkunasivam shares the inspiration for combining sasanlimab with BCG in patients with high-risk, BCG-naïve NMIBC.
Dr. Prasad provides overviews of ATLAS and ENVISION and opines on whether UGN-102 is a practice-ready alternative to TURBT.
Several urologists weigh in on BCG, its role in NMIBC treatment, shortages, and strategies to treat BCG-unresponsive disease.
The ATLAS study demonstrated the superiority of UGN-102 over TURBT for patients with low-grade, intermediate-risk NMIBC.
UGN-102 is a sustained-release, hydrogel-based formula that allows bladder tissue to be exposed to mitomycin longer.
Through molecular profiling, three different BCG response subtypes were found: BRS1, BRS2, and BRS3.
An observational study sought to determine variation in recurrence after TURBT between sites taking part in the RESECT study.
FDA approval of Adstiladrin for use in BCG-unresponsive NMIBC expands the armamentarium for treatment of high-risk NMIBC.
NMIBC-associated costs vary widely across types of treatments utilized, health systems, and regions of the country.
There is significant inter-site variation in recurrence of NMIBC after TRUBT in the RESECT study, according to new research.
Study results indicate an alternative strategy to radical cystectomy for comprehensive bladder-preserving therapy for MIBC.
No nonsurgical treatments currently exist for patients with NMIBC who did not respond to BCG therapy.
Patients with high-risk NMIBC who underwent TURBT from November 1993 to April 2019 were retrospectively evaluated.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.